Exelixis, Inc. $EXEL Shares Bought by Hsbc Holdings PLC

Hsbc Holdings PLC lifted its position in Exelixis, Inc. (NASDAQ:EXEL) by 152.9% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 65,978 shares of the biotechnology company’s stock after buying an additional 39,894 shares during the period. Hsbc Holdings PLC’s holdings in Exelixis were worth $2,837,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of EXEL. AQR Capital Management LLC grew its stake in shares of Exelixis by 48.8% in the 4th quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock worth $598,647,000 after purchasing an additional 4,477,029 shares during the last quarter. Norges Bank acquired a new position in Exelixis in the fourth quarter worth approximately $106,460,000. UBS Group AG grew its position in Exelixis by 100.1% in the third quarter. UBS Group AG now owns 2,655,069 shares of the biotechnology company’s stock worth $109,654,000 after buying an additional 1,328,087 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in shares of Exelixis by 1,821.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,188,105 shares of the biotechnology company’s stock valued at $52,075,000 after buying an additional 1,126,256 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Exelixis by 111.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,115,456 shares of the biotechnology company’s stock valued at $92,720,000 after acquiring an additional 1,113,916 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Trading Down 0.5%

Shares of Exelixis stock opened at $55.37 on Friday. The stock has a 50-day moving average price of $53.16 and a 200 day moving average price of $47.19. The company has a market cap of $13.92 billion, a P/E ratio of 18.40, a P/E/G ratio of 1.60 and a beta of 0.42. Exelixis, Inc. has a 1 year low of $33.76 and a 1 year high of $57.57.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.12. The company had revenue of $610.81 million for the quarter, compared to analysts’ expectations of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The business’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.55 EPS. On average, equities analysts forecast that Exelixis, Inc. will post 3.15 earnings per share for the current fiscal year.

Insider Buying and Selling at Exelixis

In other Exelixis news, Director Jack L. Wyszomierski sold 3,925 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $50.55, for a total value of $198,408.75. Following the transaction, the director owned 284,384 shares in the company, valued at approximately $14,375,611.20. This represents a 1.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrick J. Haley sold 32,110 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $49.81, for a total transaction of $1,599,399.10. Following the completion of the sale, the executive vice president owned 357,638 shares of the company’s stock, valued at approximately $17,813,948.78. The trade was a 8.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 219,170 shares of company stock valued at $10,620,641 in the last 90 days. Corporate insiders own 2.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on EXEL shares. Royal Bank Of Canada boosted their target price on Exelixis from $43.00 to $46.00 and gave the stock a “sector perform” rating in a research report on Tuesday, July 7th. Morgan Stanley raised their target price on shares of Exelixis from $50.00 to $53.00 and gave the stock an “equal weight” rating in a report on Thursday. Citigroup reissued a “market outperform” rating on shares of Exelixis in a research report on Wednesday. HC Wainwright restated a “buy” rating and issued a $56.00 price target on shares of Exelixis in a research report on Thursday, July 2nd. Finally, Barclays raised their price objective on shares of Exelixis from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 14th. Nine equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $49.00.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.